MRT-9643
/ Monte Rosa Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 11, 2024
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
(GlobeNewswire)
- "Monte Rosa Therapeutics, Inc...announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader to treat HR-positive/HER2-negative breast cancer at the 2024 San Antonio Breast Cancer Symposium, held December 10-13 in San Antonio, Texas....'We look forward to advancing our CDK2 MGD program towards a development candidate nomination in H1 2025'....In cellular assays, MRT-9643 induced deep CDK2 degradation, resulting in CDK2-dependent cancer cell growth inhibition....MRT-9643 demonstrated superior selectivity as compared to several clinical-stage small molecule CDK2 inhibitors evaluated. The combination of MRT-9643 and ribociclib, an FDA-approved CDK4/6 inhibitor, delayed resistance to CDK4/6 inhibition both in vitro and in vivo."
Preclinical • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer
January 08, 2024
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
(GlobeNewswire)
- "The Company expects to nominate a development candidate for the CDK2 preclinical program in 2024."
Preclinical • Oncology
November 09, 2023
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
(GlobeNewswire)
- "The Company now expects to release the recommended Phase 2 dose for the MRT-2359 Phase 1/2 study in Q2 2024. On track for planned IND submission for MRT-6160 in the first half of 2024. The Company expects to nominate a development candidate for its NEK7 preclinical program in Q1 2024. The Company expects to nominate a development candidate for its CDK2 preclinical program in 2024."
IND • P1/2 data • Pipeline update • Immunology • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1